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Niemann–Pick type C disease (NP-C) presents with heterogeneous neurological and 
psychiatric symptoms. Adult onset is rare and possibly underdiagnosed due to frequent 
lack of specific and obvious key symptoms. For both early and adolescent/adult onset, 
the available data from studies and case reports describe a positive effect of Miglustat 
(symptom relief or stabilization). However, due to the low frequency of NP-C, experi-
ence with this therapy is still limited. We describe two adult-onset cases of NP-C. In 
both cases, vertical supranuclear gaze palsy was not recognized at symptom onset. 
Correct diagnosis was delayed from onset of symptoms by more than 10 years. The 
video demonstrates the broad spectrum of symptoms in later stages of the disease. 
Compared with published data, the treatment outcome observed in our cases after 
delayed initiation of Miglustat therapy was disappointing, with continuing disease pro-
gression in both cases. Thus, early treatment initiation could be necessary to achieve a 
good symptomatic effect. Hence, early biochemical testing for NP-C should be consid-
ered in patients suffering from atypical neurological/neuropsychological and psychiatric 
symptoms, even in cases of uncertainty.
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Niemann–Pick type C (NP-C) is a rare neurodegenerative lysosomal storage disorder of autosomal 
recessive inheritance. NP-C is caused by mutations of either the NPC1 (95% of families) (1) or the 
NPC2 gene (2). The underlying pathophysiology originates from impaired lipid trafficking, resulting 
in intracellular accumulation of unesterified cholesterol and other composites in various tissues, 
including the brain (3). The estimated incidence is 1/120,000–1/150,000 live births (3). The diagnosis 
of NP-C is established by a combination of genetic biochemical (oxysterols in plasma, filipin staining 
in fibroblasts) and genetic testing, which involves NPC1/2 gene sequencing (4). The age at onset 
(AAO) of most patients is from early infancy (<2 years) to adolescent/adult onset (≥15 years) (5). 
Adult onset is rare and patients present with a very heterogeneous clinical spectrum of symptoms 
such as cognitive impairment, cerebellar symptoms, dystonia, vertical supranuclear gaze palsy 
(VSGP), psychiatric disorders and, less frequently, epilepsy (6, 7). Due to the broad phenotypic 
spectrum, NP-C is easily overlooked in adult patients, in particular because VSGP might start as 
mild, isolated vertical saccade initiation (VSI) delay. As a consequence, time from first symptoms to 
NP-C diagnosis often takes several years. This delay is crucial, as early diagnosis and the initiation of 
an approved therapy with Miglustat (Zavesca®, Actelion Pharmaceuticals, Allschwil, Switzerland)—a 
taBLe 1 | patient characteristics and imaging findings.
patient 1 patient 2
sex Female Male
Age at presentation, years 28 48
AAO, years 17 38
NPC1 mutation p.P474L/P474L p.S954L/P1007A
First symptoms Cognitive decline Cognitive decline
Onset VSGP, years 33 ?
Cognitive decline, years 17 38
Onset ataxia, years 23 ?
MRI Slight cerebral atrophy Frontotemporal and 
cerebellar atrophy
FDG-PET n.a. Normal
NPC-SI at first admission 14 (revised version) –
NPC-SI at diagnosis 76 (revised version) 76 (revised version)
AAO, age at onset; FDG-PET, fluorodeoxyglucose positron emission tomography; MRI, 
magnetic resonance imaging; NPC-SI, Niemann–Pick type C Suspicion Index tool; 
VSGP, vertical supranuclear gaze palsy; ?, unknown; n.a., not applicable.
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reversible glycosphingolipid synthesis inhibitor that can stabilize 
or slow the progression of irreversible neurological damage—is 
of great importance (8). The recently improved Niemann–Pick 
type C Suspicion Index tool (NPC-SI) helps to detect patients 
that should be tested for NP-C (9). The test is available from 
http://www.npc-si.com/. We present the clinical course of two 
genetically confirmed NP-C cases with adolescent and adult 
AAO. Patient characteristics are provided in Table 1. Video S1 
in supplementary material demonstrates clinical features of both 
patients after diagnosis.
Patient 1 (first part of the film) consulted a neurologist at the 
age of 28 years after experiencing frequent falls, ataxia, and mild 
mnestic deficits. Her parents reported a difficult, traumatic birth. 
Several developmental milestones (e.g., learning to walk or speak, 
etc.) during early childhood were achieved with a delay of several 
months. During that time, it was supposed that the condition 
comprised symptoms of infantile cerebral palsy, no hepato-, or 
splenomegaly had been observed. However, the clinical course 
during elementary and high school was unremarkable, and no 
developmental deficits were noted during that time. In the course 
of an apprenticeship at the age of 17 years, increasing difficulties 
using electrical tools forced her to quit her job. From then on, 
she was only capable of minor jobs and was finally employed 
in a protected workshop due to cognitive deficits. At the age of 
approximately 23 years, the patient developed a gait disorder that 
progressed over the following years.
During her first neurologic consultation 5 years later, clinical 
findings revealed slightly increased latency of VSI but no hypo-
metric eye movements, no ataxia, and no obvious cognitive and 
psychomotor deficits. VSI was noted but was not interpreted 
as VSGP. Family history included death of one cousin due to 
a “severe neurologic condition,” which was never accurately 
diagnosed. Magnetic resonance imaging (MRI) revealed slight 
cerebral atrophy. Electroencephalographic recordings matched 
criteria for diffuse generalized encephalopathy. General cer-
ebrospinal fluid (CSF) status was normal. The condition was 
interpreted as sequelae of the infantile cerebral palsy that had 
been presumed during childhood. NPC-SI at the time would 
have been 58 points (high likelihood of NP-C if VSGP was 
recognized) or 14 (low likelihood if VSGP was not recognized). 
During the following 3  years, symptoms progressed slowly. 
At the age of 33  years, hypometric vertical saccades were 
recognized as VSGP. An affection of the first motor neuron 
(spasticity, extensor plantar response) was noted. At the age 
of 34  years, the additional appearance of dystonic symptoms 
triggered another workup of this complex case and finally led to 
a genetic diagnosis of NP-C caused by a homozygous mutation 
of NPC1 gene (p.P474L/P474L). NPC-SI (revised version) was 
76 points (high likelihood of NP-C).
Medical therapy with Miglustat 300 mg/day was initiated and 
has been used for more than 2.5  years at the time of writing 
this report. Due to continuing symptom progression, escalation 
of the dose up to 600  mg/day was attempted twice. However, 
worsening of ataxia reported by caregivers and appearance of 
tremor forced us to reduce the drug dosage. During the course 
of treatment, the patient became almost completely mutistic and 
gait ataxia has increased to such a level that she falls frequently 
and regularly requires assistance while walking. Twelve months 
after initiation of therapy, SARA score was 28/40 points and 
increased during the following 18  months to 32/40 points. 
Dysphagia (impaired initiation of swallows, but only rare cough-
ing) and ataxia of the upper limbs cause dependence during 
many activities of daily living.
Patient 2 (second part of the film) first presented slow progres-
sive concentration/memory impairment at the age of 38  years, 
followed by gait disturbances that worsened over time. No vis-
ceral symptoms (splenomegaly, prolonged unexplained jaundice) 
had been described in childhood. He had finished junior high 
school and undergone an apprenticeship to become a mechanic. 
Afterward, he worked as a train conductor until the age of 39 years 
when he was retired prematurely due to his cognitive deficits. 
At the age of 48  years, a frontotemporal degeneration (FTLD) 
was suspected because of a slight frontotemporal and cerebellar 
pronounced atrophy on the MRI. A fluorodeoxyglucose positron 
emission tomography (FDG-PET scan) at that time was normal. 
In the CSF, the tau (592 pg/ml; ref. <450 pg/ml) and phospho-tau 
(81 pg/ml; ref. <61 pg/ml) protein were slightly increased. The 
clinical examination revealed a cerebellar ataxia (SARA score 
10/40), dysarthria, VSGP, and myocloniform movements in the 
proximal muscles. Neuropsychological testing showed deficits in 
visuo-constructive skills, working memory, and attention mem-
ory. The NPC-SI was 76 points (revised NPC-SI, high suspicion 
for NP-C). Due to the phenotype, diagnostic testing for NP-C was 
initiated, revealing increased oxysterols [0.11 ng/μl (<0.05)] in 
the serum and subsequently a compound heterozygous mutation 
in the NPC1 gene (p.S954L/P1007A). Therapy with Miglustat 
(3 × 200 mg) was started at 49 years of age. After 6 months of 
treatment, symptoms worsened due to development of frequent 
falls and apathy. Unfortunately, the patient died as a result of 
bolus aspiration at age 50.
Previous studies have shown that NP-C patients with juvenile 
or adult-onset phenotypes show even better responses to treat-
ment than patients with an early onset in terms of improvement or 
stabilization of neurological symptoms (10). The most important 
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outcome parameter to avoid worsening of neurological symptoms 
was the delay between the onset of symptoms and the initiation of 
treatment (10). The present cases of genetically confirmed NP-C 
cases exemplarily illustrate the serious dilemma of the latency in 
diagnosis of NP-C (17 years in patient 1; 10 years in patient 2). 
The Miglustat treatment that was initiated after the diagnosis was 
made was unfortunately only of little success.
The major reason for the delayed diagnosis in our two 
patients was due to the phenotypical difference between the 
early- and late-onset NP-C patients. Hepatosplenomegaly and/
or gelastic cataplexy are less frequent or missed by the lack of 
an appropriate examination in patients with an adult onset. 
Other neurological manifestations (VSGP, cerebellar ataxia, 
dystonia, and dysarthria/dysphagia) are more frequent (11), 
in our patients even a key clinical sign of NP-C, the VSGP, 
only became apparent later in the disease course or was not 
correctly recognized early in the disease course. Systematic 
studies illustrate the broad spectrum of initial symptoms in 
adolescent- or adult-onset NP-C cases: in a report on five cases 
where disease onset was between 5 and 50 years of age, ataxia 
and myoclonus appeared to be the most frequent neurologic 
symptoms, while VSGP was lacking in two patients. Koens and 
coauthors described movement disorders as primary symptom 
in three-quarters of patients, mainly myoclonus (including 
negative myoclonus) and ataxia. Psychosis was less frequent, 
while cognitive deficits appeared early in the course of the 
disease in every second patient of the cohort (11).
Brain MRI or FDG-PET imaging might be normal or unspe-
cifically changed in NP-C (6, 7), whereas specific changes have 
been described for neurodegenerative diseases such as progressive 
supranuclear palsy (PSP) or multiple system atrophy. In the past, 
lack of specific features in early stages of adult-onset NP-C led to 
a low or moderate NPC-SI score, as shown by others (6). On the 
other hand, the NPC-SI shows a high probability if it is applied in 
cases with clinical diagnoses of neurodegenerative diseases such 
as PSP or FTLD. However, a recent study in 790 patients suffering 
from PD, FTLD, or PSP and 846 age-matched controls showed 
comparable rates of NPC1/2 frequency variants for PD patients 
(1.1%) and controls (0.8%), and no polymorphism in FTLD and 
PSP patients (12). A recent study reported that NP-C could be 
identified even when patient selection is restricted to early onset 
cerebellar ataxia (13). In our view, metabolic NP-C testing should 
be offered to patients with a pre-senile cognitive decline with or 
without ataxia, VSGP with or without presentation of movement 
disorders, or psychiatric signs. The revised version of the NPC-SI 
supports screening of older cases, since it offers separate versions 
for patients below and above 4 years of age.
The finding of elevated levels of tau and phospho-tau in the CSF 
of patient 2 is particularly interesting. Gene expression data from 
fibroblasts of NPC patients suggest similarities to Alzheimer’s 
disease, where hyperphosphorylation of microtubule-binding 
protein tau reduces the microtubule-binding capability of tau 
and is associated with the formation of neurofibrillary tangles. In 
fibroblast derived from NPC patients, genes of proteins involved in 
tau phosphorylation are overexpressed in comparison to control 
cells (e.g., TTBK1, MAPK8, and PRKCG) (14). Studies in rodents 
have demonstrated increase in phenotype severity in NPC1/tau 
double null mutants, but not in tau knockout animals that carry 
the NPC1 wild-type gene (15). It also has been shown that tau 
reduction in NPC1-deficient fibroblasts—in contrast to control 
cells—decreases autophagy induction and flux (16). Systematic 
CSF analysis for tau phosphorylation levels might contribute to 
understanding of disease mechanisms and heterogeneity of clini-
cal cases.
In both cases in the present report, Miglustat therapy was 
initiated after diagnosis of NP-C. However, the disease was not 
correctly diagnosed initially, causing a delay between onset of 
symptoms of 10 and 12  years, respectively. Unfortunately, we 
could not find symptomatic relief or at least stabilization. The 
first patient developed increasing impairment of mobility, ataxia, 
and dysarthria. Similarly, the second patient had increasing 
difficulties in walking. A potential life-threatening symptom of 
NP-C, neurogenic dysphagia, was not reduced in both patients 
and probably resulted in the death of the second patient.
Systematic reports describe a robust trend toward positive 
outcomes for Miglustat treatment in adult/adolescent-onset 
patients. Results from the most comprehensive NP-C registry 
to date included data from 18 adolescent/adult-onset patients 
receiving Miglustat (14). Disease severity is illustrated by a 
disease-specific disability score. The score is composed of 
subratings for ambulation, manipulation, language, and swal-
lowing values, ranging from 0 (no impairment) to 1 (worst). 
The mean age of first symptoms in adult-onset patients was 22.7, 
while mean age at initiation of treatment was 26.7. The overall 
disability score during the observational period was stable and 
improved slightly from 0.35 (SD: 0.17) to 0.31 (SD: 0.22) (17). In 
a recent report, out of three patients that had received Miglustat 
continuously, one patient improved and two remained on a 
stable clinical level. In one patient within the same study, treat-
ment was initiated and then withdrawn after severe digestive 
side effects. This patient died due to sudden-onset swallowing 
difficulties (6).
Several factors might contribute to the discrepancy between 
the overall positive outcome in recent publications and the expe-
riences described in the present report. Patient 1 from the present 
series tolerated only a dosage of 300 mg daily, since she and her 
caregivers reported a worsening in disease severity immediately 
after increase to 600  mg, even if the dosage was increased in 
100  mg steps every second week. For patient 2, the follow-up 
period is probably too short to allow for observation of a robust 
clinical improvement. He died only 12  months after treatment 
initiation. However, one would have expected at least some kind 
of stabilization in both cases given the overall positive results of 
Miglustat therapy that have been published recently. The limited 
response might be due to the delayed initiation of treatment and 
lower dosage in one of the two cases.
In conclusion, our case reports support the notion of a hetero-
geneous phenotype and disease course of NP-C. The frequency 
of NP-C testing in routine diagnostics should increase as disease 
biomarkers such as plasma oxysterols, even if not specific for 
NP-C, have recently become more easily available. Miglustat 
has been shown to be effective in infantile and adolescent-onset 
patients, but further research is warranted in order to understand 
heterogeneous outcomes.
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VIDeo s1 | Illustration of motor symptoms in two adolescent/adult-onset 
Np-C patients. 00:00: patient 1, approximately 15 years after onset of motor 
symptoms. 00:05: demonstration of supranuclear, predominantly vertical gaze 
palsy. Inhibition of horizontal saccade initiation and pursuit movements should 
also be noted. 00:35: upper limb ataxia. 00:51: lower limb ataxia. 01:09: gait 
ataxia; disabling limb dystonia is obvious. 01:35: NP-C patient 2. 01:40: vertical 
gaze palsy. 01:56: positive applause sign. 02:08: gait ataxia. 02:13: postural 
reflexes.
